America's Pharmacy
Home Treatments and Therapies Tafasitamab Plus Lenalidomide and Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma

Tafasitamab Plus Lenalidomide and Rituximab for Follicular Lymphoma and Marginal Zone Lymphoma

0
21



Title: A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma (InMIND)

Study Director: Clinical Trials, Incyte Corporation

Description:  Researchers are conducting a phase 3 trial to investigate the efficacy and safety of tafasitamab in combination with lenalidomide and rituximab for relapsed/refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL).


Continue Reading

The trial is designed to compare tafasitamab plus rituximab and lenalidomide with placebo plus rituximab and lenalidomide.

The primary outcome measure is progression-free survival (PFS) in patients with FL. Secondary endpoints include PFS in both the FL and MZL populations, as well as complete response, overall survival, minimal residual disease negativity, safety, and quality of life.

To be eligible for the study, patients must have a diagnosis of grade 1-3a FL, nodal MZL, splenic MZL, or extranodal MZL that meets published diagnostic criteria. Patients must also be 18 years of age or older and willing to avoid pregnancy or fathering children. For a complete list of eligibility criteria, please refer to the reference.

Status: Recruiting

This study is sponsored by Incyte Corporation.

Reference

Clinicaltrials.gov. A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND). NCT04680052. Accessed October 20, 2021.




Next post in Lymphoma






Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here